ABSTRACT
Portal biliopathy is defined as abnormalities in the extra- and intrahepatic ducts and gallbladder of patients with portal hypertension. This condition is associated with extrahepatic venous obstruction and dilatation of the venous plexus of the common bile duct, resulting in mural irregularities and compression of the biliary tree. Most patients with portal biliopathy remain asymptomatic, but approximately 10% of them advance to symptomatic abdominal pain, jaundice, and fever. Magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography are currently used as diagnostic tools because they are noninvasive and can be used to assess the regularity, length, and degree of bile duct narrowing. Management of portal biliopathy is aimed at biliary decompression and reducing the portal pressure. Portal biliopathy has rarely been reported in Korea. We present a symptomatic case of portal biliopathy that was complicated by cholangitis and successfully treated with biliary endoscopic procedures.
Subject(s)
Humans , Male , Middle Aged , Abdomen/diagnostic imaging , Cholangiopancreatography, Endoscopic Retrograde , Cholestasis/diagnosis , Hypertension, Portal/diagnosis , Portal Vein , Stents , Tomography, X-Ray ComputedABSTRACT
We report on a 64-year-old man with leptomeningeal metastasis (LM) from an epidermal growth factor receptor (EGFR)-mutated adenocarcinoma of the lung. He was treated with paclitaxel, cisplatin. After completion of chemotherapy, he complained of headache, nausea, and vomiting. EGFR-mutated tumor cells were identified from the cerebrospinal fluid (CSF). Second-line therapy with gefitinib, methotrexate was started. After receiving gefitinib for 4 weeks, he had no more headaches or vomiting. Eleven months after initiation of gefitinib, he developed headache and nausea. Chest computed tomography showed aggravation of bone metastasis. Third-line therapy was started with gemcitabine and carboplatin. Two weeks later, he experienced disorientation. After a fourth relapse within the central nervous system, the therapy was switched to erlotinib and significant improvement of LM was achieved. This case shows that LM can be diagnosed by detecting EGFR mutation in CSF and EGFR tyrosine kinase inhibitors are effective for LM from EGFR mutant non-small cell lung cancer.
Subject(s)
Humans , Middle Aged , Adenocarcinoma , Carboplatin , Carcinoma, Non-Small-Cell Lung , Central Nervous System , Cerebrospinal Fluid , Cisplatin , Drug Therapy , Epidermal Growth Factor , Erlotinib Hydrochloride , Headache , Lung Neoplasms , Lung , Methotrexate , Nausea , Neoplasm Metastasis , Paclitaxel , Phosphotransferases , Protein-Tyrosine Kinases , ErbB Receptors , Recurrence , Thorax , VomitingABSTRACT
No abstract available.
Subject(s)
Female , Humans , Middle Aged , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/blood , Biomarkers/blood , Drug Therapy, Combination , Facial Dermatoses/complications , Hand Joints/physiopathology , Immunosuppressive Agents/therapeutic use , Inflammation Mediators/blood , Knee Joint/physiopathology , Lupus Erythematosus, Systemic/blood , Syndrome , Treatment OutcomeABSTRACT
An iliopsoas abscess is a collection of pus in the iliopsoas muscle caused by the direct spread of infection from adjacent internal organs or by hematogenous or lymphatic spread from distal sites. Its symptoms are vague back, hip, thigh or lower abdomen pain with insidious onset, similar to those of ankylosing spondylitis (AS). Therefore diagnosing an iliopsoas abscess in patients with AS is difficult. A forty-three year-old man was treated with adalimumab, a tumor necrosis factor inhibitor, and clinical symptoms were subsequently observed to improve. One year after voluntary discontinuation of adalimumab, the patient returned with a recurrence of right buttock pain and was diagnosed as having aggravated AS. Following re-initiation of adalimumab, symptoms did not improve and fever developed. On the basis of imaging studies, the patient was diagnosed as having an iliopsoas abscess and was successfully treated with intravenous antibiotics.
Subject(s)
Humans , Abdomen , Anti-Bacterial Agents , Buttocks , Fever , Hip , Psoas Abscess , Recurrence , Spondylitis, Ankylosing , Suppuration , Thigh , Tumor Necrosis Factor-alphaABSTRACT
Anaplastic lymphoma kinase (ALK) rearrangement, is a kind of driver mutation, accounts for 3%-5% of non-small cell lung cancer (NSCLC). NSCLC patients harboring ALK fusion genes have distinct clinical features and good response to ALK inhibitors. Metastasis from lung cancer to the ovary has rarely been known. We report a case of a 54-year-old woman with bilateral ovarian metastases from ALK rearranged NSCLC. She underwent bilateral salpingo-oophorectomy for ovary masses, which were progressed after cytotoxic chemotherapy although primary lung mass was decreased. Histopathological examination of the ovary tumor showed characteristic adenocarcinoma patterns of the lung and ALK rearrangement.